Details for New Drug Application (NDA): 210329
✉ Email this page to a colleague
The generic ingredient in TADALAFIL is tadalafil. There are twenty-five drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Summary for 210329
| Tradename: | TADALAFIL |
| Applicant: | Jubilant Generics |
| Ingredient: | tadalafil |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 210329
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2.5MG | ||||
| Approval Date: | May 15, 2026 | TE: | AB1 | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | May 15, 2026 | TE: | AB1 | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | May 15, 2026 | TE: | AB1 | RLD: | No | ||||
Complete Access Available with Subscription
